Tudor Borza1,2, Samuel R Kaufman2, Phyllis Yan2, Lindsey A Herrel1,2, Amy N Luckenbaugh2, David C Miller1,2, Ted A Skolarus1,2,3, Bruce L Jacobs4, John M Hollingsworth1,2, Edward C Norton5,6,7, Vahakn B Shahinian8, Brent K Hollenbeck1,2. 1. Division of Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan. 2. Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan. 3. Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan. 4. Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan. 6. Department of Economics, University of Michigan, Ann Arbor, Michigan. 7. National Bureau of Economic Research, Cambridge, Massachusetts. 8. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Accountable care organizations (ACOs) can improve prostate cancer care by decreasing treatment variations (ie, avoidance of treatment in low-value settings). Herein, the authors performed a study to understand the effect of Medicare Shared Savings Program ACOs on prostate cancer care. METHODS: Using a 20% Medicare sample, the authors identified men with newly diagnosed prostate cancer from 2010 through 2013. Rates of treatment, potential overtreatment (ie, treatment in men with a ≥75% chance of 10-year mortality from competing risks), and Medicare payments were measured using regression models. The impact of ACO participation was assessed using difference-in-differences analyses. RESULTS: Before implementation of ACOs, the treatment rate was 71.8% (95% confidence interval [95% CI], 70.2%-73.3%) for ACO-aligned beneficiaries and 72.3% (95% CI, 71.7%-73.0% [P = .51]) for non-ACO-aligned beneficiaries. After implementation, this rate declined to 68.4% (95% CI, 66.1%-70.7% [P = .017]) for ACO-aligned beneficiaries and 69.3% (95% CI, 68.5%-70.1% [P<.001]) for non-ACO-aligned beneficiaries. There was no differential effect noted for ACO participation. The rate of potential overtreatment decreased from 48.2% (95% CI, 43.1%-53.3%) to 40.2% (95% CI, 32.4%-48.0% [P = .087]) for ACO-aligned beneficiaries and increased from 44.3% (95% CI, 42.1%-46.5%) to 47.0% (95% CI, 44.5%-49.5% [P = .11]) for non-ACO-aligned beneficiaries. These changes resulted in a significant relative decrease in overtreatment of 17% for ACO-aligned beneficiaries (difference-in-differences, 10.8%; P = .031). Payments were not found to be differentially affected by ACO alignment. CONCLUSIONS: The treatment of prostate cancer and annual payments decreased significantly between 2010 and 2013, but ACO participation did not appear to impact these trends. Among men least likely to benefit, Medicare Shared Savings Program ACO alignment was associated with a significant decline in prostate cancer treatment. Cancer 2018;124:563-70.
BACKGROUND: Accountable care organizations (ACOs) can improve prostate cancer care by decreasing treatment variations (ie, avoidance of treatment in low-value settings). Herein, the authors performed a study to understand the effect of Medicare Shared Savings Program ACOs on prostate cancer care. METHODS: Using a 20% Medicare sample, the authors identified men with newly diagnosed prostate cancer from 2010 through 2013. Rates of treatment, potential overtreatment (ie, treatment in men with a ≥75% chance of 10-year mortality from competing risks), and Medicare payments were measured using regression models. The impact of ACO participation was assessed using difference-in-differences analyses. RESULTS: Before implementation of ACOs, the treatment rate was 71.8% (95% confidence interval [95% CI], 70.2%-73.3%) for ACO-aligned beneficiaries and 72.3% (95% CI, 71.7%-73.0% [P = .51]) for non-ACO-aligned beneficiaries. After implementation, this rate declined to 68.4% (95% CI, 66.1%-70.7% [P = .017]) for ACO-aligned beneficiaries and 69.3% (95% CI, 68.5%-70.1% [P<.001]) for non-ACO-aligned beneficiaries. There was no differential effect noted for ACO participation. The rate of potential overtreatment decreased from 48.2% (95% CI, 43.1%-53.3%) to 40.2% (95% CI, 32.4%-48.0% [P = .087]) for ACO-aligned beneficiaries and increased from 44.3% (95% CI, 42.1%-46.5%) to 47.0% (95% CI, 44.5%-49.5% [P = .11]) for non-ACO-aligned beneficiaries. These changes resulted in a significant relative decrease in overtreatment of 17% for ACO-aligned beneficiaries (difference-in-differences, 10.8%; P = .031). Payments were not found to be differentially affected by ACO alignment. CONCLUSIONS: The treatment of prostate cancer and annual payments decreased significantly between 2010 and 2013, but ACO participation did not appear to impact these trends. Among men least likely to benefit, Medicare Shared Savings Program ACO alignment was associated with a significant decline in prostate cancer treatment. Cancer 2018;124:563-70.
Authors: J Michael McWilliams; Lauren G Gilstrap; David G Stevenson; Michael E Chernew; Haiden A Huskamp; David C Grabowski Journal: JAMA Intern Med Date: 2017-04-01 Impact factor: 21.873
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2014-03-06 Impact factor: 91.245
Authors: Lindsey A Herrel; Edward C Norton; Scott R Hawken; Zaojun Ye; Brent K Hollenbeck; David C Miller Journal: Cancer Date: 2016-05-24 Impact factor: 6.860
Authors: Liam C Macleod; Jonathan G Yabes; Mina M Fam; Jathin Bandari; Michelle Yu; Avinash Maganty; Alessandro Furlan; Christopher P Filson; Benjamin J Davies; Bruce L Jacobs Journal: Eur Urol Focus Date: 2019-04-25
Authors: Parth K Modi; Samuel R Kaufman; Tudor Borza; Bryant W Oliphant; Andrew M Ryan; David C Miller; Vahakn B Shahinian; Chad Ellimoottil; Brent K Hollenbeck Journal: Surg Innov Date: 2018-11-30 Impact factor: 2.058
Authors: Parth K Modi; Samuel R Kaufman; Tudor Borza; Phyllis Yan; David C Miller; Ted A Skolarus; John M Hollingsworth; Edward C Norton; Vahakn B Shahinian; Brent K Hollenbeck Journal: Cancer Date: 2018-06-15 Impact factor: 6.860
Authors: Bruce L Jacobs; Jonathan G Yabes; Samia H Lopa; Dwight E Heron; Chung-Chou H Chang; Justin E Bekelman; Joel B Nelson; Julie P W Bynum; Amber E Barnato; Jeremy M Kahn Journal: Urology Date: 2020-01-13 Impact factor: 2.649